Lenacapavir: HIV Vaccine Could Cost as Little as $40 Per Year for Patients
Research suggests that a new antiretroviral drug, Lenacapavir could transform HIV prevention and treatment. Currently priced at over $40,000 annually per patient, Some say that the drug’s cost could be slashed to just $40 per year if produced generically.